In contrast, when evaluating the AR negative LAPC9 CRPC model which has primary resistance to enzalutamide, in vivo anti-tumor activity was seen with single agent venetoclax, but there was no additional benefit with the addition of enzalutamide in organoid studies [191]. Here, AR is linked to neoplasm.